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Introduction. Because the specific proton beam dose distribution (i.e. the so-called ’Bragg curve’), proton radiotherapy 
ensures that the high-dose region is precisely confined to the target volume while minimizing the dose delivered to 
healthy tissues/critical organs surrounding the tumour or to those lying in the path of the proton beam. This method 
has been used for patients in Kraków since November 2016.
Aim. To report the early tolerance outcomes to proton radiotherapy in patients completing their treatment just 
before the end of August 2017.
Materials and methods. Study subjects were 47 patients who had completed their treatment before the end of 
August 2017 with a mean age of 41.6 years (range: 16–76, median: 40). The most frequent diagnoses were skull base 
tumours (22 pts. — 46.8%) and brain G1 or G2 gliomas (17 pts. — 36.2%), whereas the most frequent histological types 
were chordomas (17 pts. — 36.2%). Proton radiotherapy was administered by pencil beam scanning and consisted 
of using the intensity modulated proton therapy (IMPT) technique. The total dose given per cancer type averaged as 
follows: (i) 70 and 74 Gy(RBE), for respectively chodrosarcomas and chordomas, (ii) 54 Gy(RBE) for brain gliomas and 
(iii) 70 Gy(RBE) for paranasal sinuses tumours. 
Early tolerance was prospectively evaluated and measured according to the CTCAE scale, version 4.03.
Results. In all, 91 side effects (SE) were recorded in 44 patients. The intensity of SEs were as following: 62 SEs (68.1%) 
were of grade 1 intensity, 21 SEs (23.1%) were of grade 2 and 8 SEs (8.8%) were of grade 3. The most frequently de-
veloped SEs were skin reactions (29 pts. — 61.7%) or oral/pharyngeal mucositis (20 pts. — 42.6%). 
Because the patient follow-up period was short, presented results only describes the early tolerance to this the-
rapy. Our findings of mild intensities for the most early side effects, at (grades 1 or 2) are consistent with other 
published studies. 
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Introduction
Using proton beams for radiotherapy was first proposed 
by Robert R. Wilson in his paper published in 1946 [1]. He 
pointed out that protons have advantages over photons 
because of their physical properties. Their specific energy 
deposition is responsible for the unique characteristic of 
dose distribution (i.e. the so-called ‘Bragg curve’) where 
negligible doses are deposited distal to the Bragg peak [1–4].
In contrast to photon radiotherapy, proton radiothera-
py ensures a greater precision in confining the high-dose 
region to the target volume while minimizing the dose 
delivered to healthy tissues and/or critical organs surroun-
ding the tumour, or to those lying in the path of the proton 
beam [1–7]. In theory, proton radiotherapy enables dose 
escalation without increasing the risk of side effects (SE) or 
complications. The clinical benefits of proton radiotherapy 
are thus to either improve local control or in reducing toxi-
city [8–11]. The physical properties of protons enable clinical 
indications to be determined, especially in radio-resistant 
tumours localized within critical organs [6, 7].
There are two methods of proton beam delivery: pas-
sive scattering and active beam scanning. In the case of 
passive scattering (SOBP — Spread-Out Bragg Peak),with 
the intention of ensuring target coverage, spread Bragg 
peak is created with the help of a range modulator, e.g. 
by a modulation wheel. In the active scanning method, 
the narrow pencil beam is moved by means of magnetic 
deflection. The dose is delivered to the target volume spot 
by spot in successive layers at different depths (starting 
from the deepest at the highest energy). The energy of the 
proton beam changes the Bragg peak depth. The active 
pencil beam scanning method enables using the intensity-
-modulated proton therapy (IMPT) method in proton radio-
therapy. There are two different possible ways of optimising 
the dose: single-field optimization (SFO) and multi-field 
optimization (MFO) [4, 8].
A proton radiotherapy procedure for patients with no-
nocular malignancies, (a proton radiotherapy procedure for 
patients with uveal melanomas performed since 2011), was 
developed thanks to a collaboration between two Polish 
institutions: the Kraków branch of the Maria Skłodowska-
-Curie Memorial Cancer Centre and Institute of Oncology, 
(COI-OK) responsible for the medical side and the Henryk 
Niewodniczański Institute of Nuclear Physics at the Polish 
Academy of Sciences (IFJ PAN) in Kraków (cyclotron owner 
and procurer of the proton beam). The first patients un-
derwent proton radiotherapy in November 2016 [12–15]. 
Eligibility criteria were specified in the Ordinance of the 
Minister of Health published 6th June 2016 [16].
This study aims to describe early tolerance to proton 
radiotherapy in a group of patients who had completed their 
treatment just prior to the end of August 2017. 
Materials and methods
Patients
Between November 2016 and August 2017, 68 patients 
from the COI-OK underwent a course of proton radiotherapy. 
At the time the present analysis was conducted, i.e. towards 
the end of August 2017, 47 patients (69.1%) had completed 
their treatment and who constitute the subjects of this study. 
Their mean age was 41.6 years (range: 16–76, median: 40). 
Table I presents the clinicopathological and treatment 
characteristics of the 47 patient subjects.
The most frequent diagnoses were skull base tumours 
(22 pts. — 46.8%) and brain gliomas (17 pts. — 36.2%), 
whereas the most frequent histological types of malignancy 
were as follows: chordomas (17 pts. — 36.2%), brain gliomas 
G1 (11 pts. — 23.4%) and chondrosarcomas (9 pts. — 19.1%). 
Proton radiotherapy
This was given as an adjuvant therapy following surgery 
(neurosurgery) on 40 patients (85.1%), who had either rece-
ived ensuing microscopically non-radical surgical treatment 
(24 patients — 51,1%) or as a result of local recurrence (in 
16 patients — 34%). In the other 7 patients (14.9%), proton 
radiotherapy was administered after a biopsy (in this case 
a diagnostic procedure to confirm the presence of a mali-
gnancy). 
Proton radiotherapy was given by means of pencil beam 
scanning generated by the Proteus-235 cyclotron located at 
the Bronowice Cyclotron Centre (CCB) IFJ PAN. The energy 
spectrum of the protons averaged from 70 to 230 MeV.
For proton radiotherapy planning purposes, an Eclipse 
treatment external beam planning system (Varian Medical 
Systems v. 7.13) was employed for all our patients. Inverse 
planning rules were used for SFO (2 patients — 4.3%) or 
MFO (45 patients — 95.7%) based on the intensity modu-
lated proton therapy (IMPT) technique. The robustness of 
each plan regarding the 2 mm range uncertainties and 
dose uncertainties of 3.5% in the scanning proton beam 
range were used for ’ the worst scenario’ analysis method.
The radiotherapy dose was prescribed in terms of the 
RBE (relative biological effectiveness) weighted absorbed 
dose — Gy(RBE). The single RBE value equalled 1.1 for pro-
tons applied in the treatment planning system. The classical 
fractionation schedule was used; the fractional dose ranging 
between 1.8 and 2.0 Gy(RBE).
The total dose according to type of the malignancy type 
averaged as follows: (i) 70 and 74 Gy(RBE) for respectively 
chodrosarcomas and chordomas, (ii) 54 Gy(RBE) for brain 
gliomas and (iii) 70 Gy(RBE) for paranasal sinuses tumours. 
Tolerance to proton radiotherapy
During the treatment period the tolerance was prospecti-
vely evaluated and measured twice weekly as well as during all 
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follow up visits. The early side effects/complications were deta-
iled by a physician and measured according to the CTCAE scale 
(Common Terminology Criteria of Adverse Events), version 4.03.
Results
During the course of the proton radiotherapy, there were 
91 side effects (SE) recorded in 44 patients; the remaining 
3 patients being without any side effects. The intensity of 
83 SEs (91.2%) was mild, with 62 SEs (68.1%) being grade 1 
intensity, 21 SEs (23.1%) of grade 2 intensity and the other 
8 SEs (8.8%) of moderate intensity (grade 3).
Table II presents the side effects and their intensity grade 
according to the irradiated anatomical regions. 
Skin reactions (dermatitis) were observed in 29 patients 
(61.7%). Mucous reactions (mucositis) in the pharynx or 
oral cavity were found in 20 patients (42.6%), of whom all 
received radiotherapy in the head and neck region (H&N): 16 
patients had skull base tumours, 3 patients with paranasal 
sinuses tumours and 1 patient with a cervical spine tumour. 
Alopecia occurred in 11 patients (23.4%) treated for brain 
gliomas (9 pts.) or skull base tumours (2 pts.). Ten patients 
(21.3%) experienced pain, with 50% suffering headaches; 
being mainly those treated for brain gliomas. Middle ear 
effusion developed in 9 patients (19.1%). Other complica-
tions occurring during proton radiotherapy included na-
usea (7 pts. — 10.6%), anorexia (4 pts. — 9.5%) and fatigue 
(4 pts. — 9.5%). 
Grade 3 side effects developed in 5 out of the 29 patients 
(17.2%) who had developed dermatitis and in 3 out of 20 
cases (15%) where mucositis occurred. It should however be 
pointed out that none of our patients needed to discontinue 
radiotherapy. Furthermore, these complications completely 
subsided during the time between completed proton radio-
therapy and the first follow-up visit.
Discussion and conclusions 
Our findings as outlined above do not significantly differ 
from other published studies. Nevertheless, in our case we 
Table I. Clinicopathological and therapeutic characteristics of the 47 patient group undergoing proton radiotherapy
Feature Number of patients %
Age ≤ 40
> 40
26
21
55.3
44.7
Gender Female
Male
23
24
48.9
51.1
Clinical diagnosis according to: 
ICD-10 code: Anatomical regions:
C41 Skull base 
Cervical or lumbo-sacral spinal region
22
5
46.8
10.6
C71 Brain 17 36.2
C31 Paranasal sinuses 3 6.4
Histological diagnosis of malignancy
Chordoma
Chondrosarcoma
Glioma G1
Glioma G2
Adenoid cystic carcinoma
Mucoepidermoid carcinoma
Esthesioneuroblastoma
17
9
11
6
2
1
1
36.2
19.1
23.4
12.8
4.3
2.1
2.1
Proton radiotherapy 
After surgery:
Microsopically non-radical
Recurrence
After biopsy (only)
24
16
7
51.1
34.0
14.9
Optimization treatment plan method:
MFO (multi-field optimization)
SFO (single-field optimization)
45
2
95.7
4.3
C41 C71 C31
Mean dose [Gy(RBE)] according to ICD-10 74.0 54.0 70.0
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administered proton radiotherapy based on pencil beam 
scanning in Kraków for 10 months. The follow-up period for 
our patients was too short to fully assess the tumour respon-
se to proton radiotherapy. Our study only thus describes the 
early tolerance outcomes of patients for this type of therapy. 
We have demonstrated that the intensity of most early side 
effects was mild with grades 1 and 2 predominating (91% 
of all SEs). Indeed, these observations are in line with those 
reported in other studies [11, 17–19]. 
Combs et al. [20] studied proton and other ion therapies 
given to patients suffering from skull base or brain tumours 
and found that the most frequent stage SEs included hair 
loss in 37% of cases, and headaches and fatigue in 27% of 
cases. Our study showed that similar SEs were rarely obse-
rved in the 39 patients with tumours at similar anatomical 
regions (i.e. the skull base or brain) and consisted of hair 
loss in 25.6% of cases, fatigue in 10.3% and headaches in 
20.5%. In addition , these patients also experienced nausea 
(12.3%) and middle ear effusion (23.1%), in keeping with 
other published studies [18, 19]. 
A study by Grosshaus et al. [19] on 15 patients with skull 
base tumours demonstrated that they all experienced side 
effects of either grade 1 or grade 2 intensity with the most 
common being low-grade fatigue (10 pts.) or nausea (8 pts.). 
Feuwert et al. [18] showed that all their patient subjects 
who had undergone proton radiotherapy on the skull base 
developed grade 1 or grade 2 early side effects. 
The aforementioned studies [17–19] also showed that 
the side effects/complications which developed on the skin 
during proton radiotherapy consisted of mild erythema but 
this contrasted with our own study observations. Five out of 
47 (10.6%) patients had grade 3 side effects which affecting 
the skin (dermatitis developed in 5 patients) which coexi-
sted with grade 3 side effects affecting the oral/pharynx 
mucous membrane in 3 patients (i.e. mucositis developed 
in 2 patients treated for tumours located at the skull base 
or in the paranasal sinuses in 1 patient). 
The early side effects of the intensities experienced by 
our patients is interesting. Because a proton beam has a re-
latively low entrance dose, the expected tolerance to this 
Table II. The type of early-stage side effects and their severity (graded by the CTCAE scale) according to irradiated anatomical regions
Type of complications Grade Skull base tumours
N = 22  
(100%)
Brain gliomas
N = 17
(100%)
Paranasal sinuses tumours
N = 3
(100%)
C or L-S* spine
tumours
N = 5% (100%)
Dermatitis G0
G1
G2
G3
13 (59.1%)
7 (31.8%)
1 (4.5%)
1 (4.5%)
4 (23.5%)
9 (52.1%)
3 (17.6%)
1 (5.9%)
–
1 (33.3%)
1 (33.3%)
1 (33.3%)
1 (20%)
2 (40%)
–
2 (40%)
Mucositis
(oral/pharynx)
G0
G1
G2
G3
6 (27.3%)
12 (54.5%)
2 (9.1%)
2 (9.1%)
17 (100%)
–
–
–
–
1 (33.3%)
1 (33.3%)
1 (33.3%)
4 (80%)
–
1 (20%)**
–
Alopecia (temporary) G0
G1
G2
21 (95.5%)
1 (4.5%)
–
8 (47.1%)
4 (23.5%)
5 (29.4%)
2 (66.7%)
1 (33.3%)
–
5 (100%)
–
–
Pain G0
G1
G2
17 (77.3%)
4 (18.2%)
1 (4.5%)
14 (82.4%)
2 (11.8%)
1 (5.9%)
3 (100%)
–
–
4 (80%)
–
1 (20%)
Middle ear effusion G0
G1
G2
13 (59.1%)
8 (36.4%)
1 (4.5%)
17 (100%)
–
–
3 (100%)
–
–
5 (100%)
–
–
Nausea G0
G1
G2
17 (77.3%)
3 (6,4%)
2 (13.6%)
17 (100%)
–
–
3 (100%)
–
–
5 (100%)
–
–
Anorexia G0
G1
18 (81.8%)
4 (18.2%)
17 (100%)
–
3 (100%)
–
5 (100%)
–
Fatigue G0
G1
G2
18 (81.8%)
3 (13.6%)
1 (4.5%)
17 (100%)
–
–
3 (100%)
–
–
5 (100%)
–
–
*C or L-S: cervical or lumbo-sacral spine region; **patient with tumour located in the cervical spine
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treatment should prove to be rather satisfactory. Treatment 
volumes are however complex targets of variable thickness 
and depths for which the proton energy requires modula-
tion so as to cover the necessary area. This procedure may 
cause significant losses in skin-sparing effects, especially 
in those targets requiring modulation (i.e. targets in close 
proximity to the skin) [21]. 
In summary, the advantage of proton radiotherapy is to 
reduce the integral dose, being partly due to the absence 
of an exit dose beyond the Bragg peak. The other factor 
reducing the integral dose is pencil beam scanning where 
the delivery of proton radiotherapy generates secondary 
neutrons only inside the patient’s body, as opposed to the 
passive scattered method where neutrons are generated 
both in the treatment head and inside the patient [22]. 
Decreasing the integral dose leads to a reduced risk of se-
condary cancer [23–25]. 
Our modest experience of using proton radiotherapy 
together with that of other published studies confirm the 
potential therapeutic benefits of this treatment method. 
Nevertheless, proton radiotherapy remains an experimental 
method, and requires hard clinical evidence from prospec-
tive clinical trials to confirm such findings.
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